About Innocoll

Innocoll is a specialty pharmaceutical company committed to improving the status quo and finding answers to unmet needs

XARACOLL®

Our lead investigational product is a drug-device surgical implant being developed for potential uses in addressing postsurgical pain

Latest News

Louis Pascarella Appointed Chief Executive Officer of Innocoll

Louis Pascarella has been named the company’s Chief Executive Officer and a member of Innocoll’s Board of Directors. Pascarella, who will retain his current role of President, succeeds Rich Fante, who is stepping down after a successful tenure as CEO and has agreed to serve as an adviser to Innocoll’s Board for at least the next year to ensure a smooth transition.
Read More

Innocoll Holdings Limited Appoints Richard Fante as Chief Executive Officer

ATHLONE, Ireland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Innocoll Holdings Limited (“Innocoll”), a specialty pharmaceutical company wholly owned by Gurnet Point Capital, announced...
Read More

Innocoll and Gurnet Point Announcement relating to the Scheme becoming Effective

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO...
Read More